Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Cash from Financing Activities (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Cash from Financing Activities readings, the most recent being $687000.0 for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 98.99% to $687000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $14.6 million, a 91.7% decrease, with the full-year FY2025 number at $14.6 million, down 91.7% from a year prior.
  • Cash from Financing Activities hit $687000.0 in Q4 2025 for Avalo Therapeutics, down from $14.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $108.6 million in Q1 2024 to a low of -$14.8 million in Q2 2022.
  • Median Cash from Financing Activities over the past 5 years was $5.7 million (2023), compared with a mean of $19.2 million.
  • The widest YoY moves for Cash from Financing Activities: up 6770800.0% in 2024, down 178.93% in 2024.
  • Avalo Therapeutics' Cash from Financing Activities stood at $76000.0 in 2021, then grew by 7.89% to $82000.0 in 2022, then crashed by 98.78% to $1000.0 in 2023, then soared by 6770800.0% to $67.7 million in 2024, then tumbled by 98.99% to $687000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were $687000.0 (Q4 2025), $14.4 million (Q3 2025), and -$469000.0 (Q2 2025) per Business Quant data.